Autonomic Nervous System Drugs Practice Questions

Q: The use of succinylcholine is not contraindicated in which of the following conditions?

Hepatic failure. **Explanation:** The core concept behind the contraindications of **Succinylcholine (SCh)**, a depolarizing neuromuscular blocker, is its tendency to cause **hyperkalemia** and increase **intracranial pressure (ICP)**. **Why Hepatic Failure is the Correct Answer:** Succinylcholine is metabolized by **pseudocholinesterase** (plasma cholinesterase), which is synthesized in the liver. In hepatic failure, levels of this enzyme may be low, leading to a **prolonged duration of action** (apnea). However, this is a *precaution* rather than an absolute contraindication. SCh does not worsen the underlying liver disease, nor does liver disease trigger the life-threatening hyperkalemic response seen in the other options. **Why the other options are Incorrect:** * **Tetanus & Cerebral Stroke (C):** These conditions involve upper motor neuron lesions or prolonged immobilization. This leads to the **upregulation of extrajunctional nicotinic receptors**. When SCh acts on these receptors, it causes massive potassium release from muscles, leading to severe, potentially fatal **hyperkalemia** and cardiac arrest. * **Closed Head Injury (B):** SCh causes fasciculations that can increase **intracranial pressure (ICP)** and intraocular pressure. In a head injury where ICP is already compromised, SCh is generally avoided to prevent secondary brain injury. **NEET-PG High-Yield Pearls:** 1. **Drug of Choice:** SCh is the drug of choice for **Rapid Sequence Induction (RSI)** due to its fastest onset (30-60s) and shortest duration (5-10 mins). 2. **Malignant Hyperthermia:** SCh is a notorious trigger; the antidote is **Dantrolene**. 3. **Phase II Block:** Occurs with high doses or continuous infusion, where the block behaves like a non-depolarizing one. 4. **Genetic Variation:** Patients with atypical pseudocholinesterase (detected by **Dibucaine number**) experience prolonged paralysis after SCh administration.

Q: Therapeutic use of acetylcholine is not possible because it is -

Rapidly degraded. **Explanation:** Acetylcholine (ACh) is the primary neurotransmitter of the parasympathetic nervous system, but it has **no clinical therapeutic utility** primarily because it is **rapidly degraded**. **1. Why "Rapidly Degraded" is correct:** ACh is a substrate for two major enzymes: **Acetylcholinesterase (AChE)**, found at synaptic clefts, and **Butyrylcholinesterase (Pseudocholinesterase)**, found in the plasma and liver. These enzymes hydrolyze ACh within milliseconds of administration. Consequently, even when given intravenously, it cannot reach target receptors in sufficient concentrations or for a long enough duration to produce a meaningful clinical effect. Furthermore, it lacks receptor selectivity, acting on both Muscarinic and Nicotinic receptors throughout the body. **2. Why other options are incorrect:** * **Highly protein bound:** ACh is a small, polar quaternary ammonium compound; it does not show significant plasma protein binding. * **Rapidly excreted:** While it is cleared quickly, the rate-limiting step for its inactivity is metabolic hydrolysis, not renal excretion. * **Orally ineffective:** While true (it is destroyed by gastric acid and esterases in the gut), this is not the primary reason it isn't used. Even if given parenterally, its rapid degradation in the blood renders it useless. **High-Yield Clinical Pearls for NEET-PG:** * **Synthetic Analogs:** To overcome rapid degradation, synthetic choline esters like **Bethanechol** and **Carbachol** were developed. They are resistant to AChE and have a longer duration of action. * **Miochol-E:** A stabilized form of ACh is used intraocularly *only* during ophthalmic surgery (e.g., cataract surgery) for immediate miosis, as it can be applied directly to the site of action. * **Structure:** ACh is a quaternary ammonium compound, meaning it is permanently charged and **cannot cross the Blood-Brain Barrier (BBB)**.

Q: What is the most common drug used for prophylaxis of migraine?

Propranolol. **Explanation:** **Propranolol** is considered the **first-line drug of choice** for the continuous prophylaxis of migraine. It is a non-selective beta-blocker that works by stabilizing vascular tone, reducing central catecholaminergic hyperactivity, and inhibiting the cortical spreading depression (CSD) associated with migraine pathophysiology. It is particularly effective in patients with co-existing hypertension or anxiety. **Analysis of Options:** * **A. Sumatriptan:** This is a 5-HT$_{1B/1D}$ receptor agonist used for the **acute treatment** of migraine attacks to abort the headache. It is never used for prophylaxis because frequent use can lead to "medication overuse headache." * **C. Valproate:** While sodium valproate is an effective prophylactic agent (especially for patients with comorbid epilepsy), it is generally considered a second-line option due to its side-effect profile (weight gain, hair loss, and teratogenicity). * **D. Flunarizine:** This is a calcium channel blocker used for prophylaxis, particularly in Europe and India. However, due to its side effects (sedation and weight gain) and slower onset of action, it is usually not the first choice over beta-blockers. **High-Yield Clinical Pearls for NEET-PG:** * **Prophylaxis Criteria:** Indicated if attacks occur $>2-3$ times per month or are severely disabling. * **Contraindications for Propranolol:** Avoid in patients with bronchial asthma, heart block, or peripheral vascular disease (Raynaud’s). * **Other Prophylactic Agents:** Amitriptyline (DOC if comorbid depression/insomnia), Topiramate (DOC if the patient is obese, as it causes weight loss), and CGRP antagonists (e.g., Erenumab) for refractory cases. * **DOC in Pregnancy:** Magnesium or low-dose Propranolol (though lifestyle changes are preferred). Avoid Valproate (Category X for migraine).

Q: Which of the following is an example of a long-acting neuromuscular blocker?

Pancuronium. **Explanation:** Neuromuscular blocking agents (NMBAs) are classified based on their chemical structure and, more clinically relevant for the NEET-PG, their **duration of action**. **1. Why Pancuronium is Correct:** **Pancuronium** is a long-acting, non-depolarizing steroid-based NMBA. It typically has a duration of action exceeding **60–90 minutes**. It is primarily excreted by the kidneys, meaning its action is significantly prolonged in patients with renal failure. **2. Analysis of Incorrect Options:** * **Rocuronium (Option A):** An intermediate-acting steroid derivative. It is highly high-yield because it has the **fastest onset of action** (60–90 seconds) among non-depolarizing blockers, making it an alternative to Succinylcholine for Rapid Sequence Induction (RSI). * **Vecuronium (Option B):** An intermediate-acting steroid derivative (duration ~30–40 minutes). It is noted for its cardiovascular stability. * **Atracurium (Option D):** An intermediate-acting benzylisoquinoline. It is unique because it undergoes **Hofmann elimination** (spontaneous degradation in plasma), making it the drug of choice in patients with liver or kidney failure. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Long-acting:** "Pipe and Pan" (**Pipecuronium** and **Pancuronium**). * **Vagolytic Effect:** Pancuronium causes tachycardia by blocking muscarinic receptors in the heart; avoid in patients where tachycardia is detrimental. * **Drug of Choice in Renal/Hepatic Failure:** Atracurium or **Cisatracurium** (Cisatracurium is more potent and produces less histamine). * **Shortest Acting NMBA:** **Succinylcholine** (Depolarizing) or **Gantacurium** (Non-depolarizing, ultra-short). * **Reversal Agent:** Sugammadex is specifically used to reverse steroid-based NMBAs (Rocuronium > Vecuronium > Pancuronium).

Q: Maximum duration of action is seen with which of the following drugs?

Pancuronium. **Explanation:** The duration of action of neuromuscular blocking agents (NMBAs) is primarily determined by their chemical structure and metabolism. NMBAs are classified into short, intermediate, and long-acting agents. **Why Pancuronium is correct:** Pancuronium is a long-acting, non-depolarizing neuromuscular blocker of the aminosteroid group. It has a duration of action typically ranging from **60 to 120 minutes**. Its long half-life is due to its reliance on renal excretion (approx. 80%) and minimal hepatic metabolism. In the context of the options provided, it has the longest duration. **Analysis of incorrect options:** * **Atracurium:** This is an intermediate-acting benzylisoquinolone. It has a duration of **30–45 minutes**. It is unique because it undergoes **Hofmann elimination** (spontaneous non-enzymatic degradation), making it safe in renal or hepatic failure. * **Rocuronium:** This is an intermediate-acting aminosteroid with a duration of **30–40 minutes**. It is favored for its rapid onset of action, making it an alternative to Succinylcholine for rapid sequence intubation. * **Rapcuronium:** This was a short-acting agent (duration **15–20 minutes**) but was withdrawn from the market due to the high risk of severe bronchospasm. **High-Yield Clinical Pearls for NEET-PG:** * **Longest acting NMBA:** Doxacurium (Pipecuronium and Pancuronium are also in the long-acting category). * **Shortest acting non-depolarizing NMBA:** Mivacurium (metabolized by plasma cholinesterase). * **Drug of choice in Renal Failure:** Atracurium or Cisatracurium (due to Hofmann elimination). * **Vagolytic effect:** Pancuronium can cause tachycardia by blocking muscarinic receptors in the heart. * **Specific Reversal Agent:** Sugammadex is used specifically for aminosteroids (Rocuronium > Vecuronium > Pancuronium).

Q: Which antiglaucoma drugs are safe to use in a patient with asthma?

Betaxolol. The primary concern when using beta-blockers in patients with asthma is the risk of **bronchospasm**. This occurs due to the blockade of **β$_2$ receptors** in the bronchial smooth muscle, which normally mediate bronchodilation. **1. Why Betaxolol is the correct answer:** Betaxolol is a **cardioselective (β$_1$ selective)** adrenoceptor antagonist [1, 2]. Because it primarily targets β$_1$ receptors (found mainly in the heart) and has minimal affinity for β$_2$ receptors, it is significantly safer for the respiratory system [1]. While no beta-blocker is 100% safe in severe asthma, betaxolol is the preferred topical beta-blocker when such therapy is necessary for a patient with reactive airway disease [1]. **2. Why the other options are incorrect:** * **Timolol:** This is a **non-selective** beta-blocker (β$_1$ + β$_2$) [1]. Even when administered topically as eye drops, systemic absorption via the nasolacrimal duct can cause life-threatening bronchospasm in asthmatic patients. It is the most common antiglaucoma drug associated with this side effect [1]. * **Propranolol:** This is a prototypical non-selective beta-blocker [1]. It is not used topically for glaucoma and is strictly contraindicated in asthma due to its potent β$_2$ blocking effects [1]. **Clinical Pearls for NEET-PG:** * **Mechanism in Glaucoma:** Beta-blockers reduce intraocular pressure (IOP) by **decreasing the production of aqueous humor** from the ciliary body [1]. * **Systemic Absorption:** To minimize systemic side effects of eye drops, advise patients to perform **nasolacrimal occlusion** (pressing the inner corner of the eye) for 1-2 minutes after instillation. * **Other Safe Alternatives:** In asthmatics, if beta-blockers are risky, consider **Prostaglandin analogues** (Latanoprost) or **Carbonic anhydrase inhibitors** (Dorzolamide).

Q: Which drugs would antagonize the interaction of catecholamines with adrenergic receptors?

Yohimbine. **Explanation:** The question asks for a drug that **antagonizes** (blocks) the interaction of catecholamines with adrenergic receptors. **1. Why Yohimbine is Correct:** Yohimbine is a selective **$\alpha_2$-adrenergic receptor antagonist**. By binding to these receptors, it prevents catecholamines (like norepinephrine) from interacting with them. While it was historically used for erectile dysfunction, its clinical use is now limited. In pharmacology, it serves as the classic prototype for $\alpha_2$ blockade. **2. Why the Other Options are Incorrect:** * **Methyldopa:** This is a centrally acting **sympatholytic**, but it does not act as a receptor antagonist. It is a prodrug converted to $\alpha$-methylnorepinephrine, which acts as an **agonist** at central $\alpha_2$ receptors to decrease sympathetic outflow. * **Clonidine:** This is a selective **$\alpha_2$-receptor agonist**. It stimulates presynaptic receptors in the brainstem, leading to a reduction in peripheral sympathetic tone. It is used in hypertension and opioid withdrawal. * **Phenylephrine:** This is a selective **$\alpha_1$-receptor agonist**. It mimics the action of catecholamines to cause vasoconstriction and mydriasis; it does not antagonize them. **High-Yield Clinical Pearls for NEET-PG:** * **$\alpha$-Blocker Classification:** Remember **Phentolamine** (Non-selective), **Prazosin** (Selective $\alpha_1$), and **Yohimbine** (Selective $\alpha_2$). * **Reversal of Action:** $\alpha$-blockers can cause "Dale’s Vasomotor Reversal," where the pressor effect of adrenaline is converted to a depressor effect. * **Drug of Choice:** Methyldopa remains a preferred drug for **hypertension in pregnancy** (along with Labetalol and Hydralazine). * **Clonidine Side Effect:** Sudden withdrawal can lead to **rebound hypertension** due to a sympathetic surge.

Q: Cinnarizine, used for motion sickness, is a:

H1 antagonist. **Explanation:** **Cinnarizine** is a piperazine derivative that primarily acts as a **sedating H1 receptor antagonist**. Its efficacy in motion sickness is attributed to its ability to inhibit the vestibular system. It suppresses the stimulation of the labyrinth by blocking H1 receptors in the vestibular nuclei and the chemoreceptor trigger zone (CTZ), thereby preventing nausea, vomiting, and vertigo. **Analysis of Options:** * **Option B (H1 antagonist):** This is the most specific pharmacological classification. Cinnarizine blocks H1 receptors and also possesses weak anticholinergic and calcium channel blocking properties, which contribute to its anti-vertigo effects. * **Option A (5HT4 antagonist):** 5HT4 receptors are primarily involved in gastrointestinal motility (prokinetics). Drugs like Prucalopride act here; Cinnarizine has no significant activity at this receptor. * **Option C (Antihistamine):** While Cinnarizine is an antihistamine, in competitive exams like NEET-PG, if both "Antihistamine" and "H1 antagonist" are provided, **H1 antagonist** is the more precise pharmacological description of its mechanism. * **Option D (NK1 antagonist):** Neurokinin-1 (NK1) antagonists, such as **Aprepitant**, are used for chemotherapy-induced nausea and vomiting (CINV), not typically for motion sickness. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC) for Motion Sickness (Prophylaxis):** Hyoscine (Scopolamine) is the most effective, usually administered as a transdermal patch. * **Cinnarizine’s Unique Property:** It is also a **T-type calcium channel blocker**, which helps in improving peripheral circulation and is used in Meniere’s disease. * **Side Effects:** Significant sedation and, with chronic use in the elderly, **drug-induced parkinsonism** (due to weak D2 blocking activity).

Q: Neostigmine used in the treatment of myasthenia gravis acts by:

Decreasing breakdown of acetylcholine. **Explanation:** **Mechanism of Action (Why C is correct):** Neostigmine is a **reversible anticholinesterase** agent. In Myasthenia Gravis (MG), there is a functional deficiency of nicotinic acetylcholine receptors (Nm) at the neuromuscular junction due to autoantibodies. Neostigmine acts by inhibiting the enzyme **Acetylcholinesterase (AChE)**, which is responsible for the hydrolysis of acetylcholine (ACh). By blocking this enzyme, Neostigmine prevents the breakdown of ACh, leading to an increased concentration and prolonged persistence of ACh in the synaptic cleft. This allows the available ACh to compete more effectively for the remaining functional receptors, thereby improving muscle strength. **Analysis of Incorrect Options:** * **Option A:** Neostigmine does not increase the number of receptors; it maximizes the utility of existing ones. * **Option B:** It has no direct effect on the choline acetyltransferase enzyme or the rate of ACh synthesis. * **Option D:** This is the opposite of its pharmacological effect; increasing degradation would worsen myasthenic symptoms. **High-Yield Clinical Pearls for NEET-PG:** * **Quaternary Ammonium Structure:** Neostigmine is a polar compound; it **does not cross the Blood-Brain Barrier (BBB)**, making it ideal for peripheral action without CNS side effects. * **Direct Action:** Unlike physostigmine, neostigmine also has a small **direct agonist effect** on nicotinic receptors. * **Drug of Choice:** It is commonly used for the symptomatic treatment of MG and for reversing the effect of non-depolarizing muscle relaxants (e.g., d-Tubocurarine). * **Side Effects:** Muscarinic effects (miosis, bradycardia, salivation) are common and can be managed with **Atropine**.

Question 1

The use of succinylcholine is not contraindicated in which of the following conditions?

Accepted Answer

Hepatic failure

Answer

Tetanus

Answer

Closed head injury

Answer

Cerebral stroke

Question 2

Therapeutic use of acetylcholine is not possible because it is -

Accepted Answer

Rapidly degraded

Answer

Highly protein bound

Answer

Rapidly excreted

Answer

Orally ineffective

Question 3

What is the most common drug used for prophylaxis of migraine?

Accepted Answer

Propranolol

Answer

Sumatriptan

Answer

Valproate

Answer

Flunarizine

Question 4

Which of the following is an example of a long-acting neuromuscular blocker?

Accepted Answer

Pancuronium

Answer

Rocuronium

Answer

Vecuronium

Answer

Atracurium

Question 5

Vasomotor reversal of Dale is demonstrated by

Accepted Answer

Fall in blood pressure by adrenaline pretreated with phentolamine

Answer

Fall in blood pressure by high dose intravenous Acetylcholine

Answer

Increase in blood pressure following administration of IV propranolol

Answer

Fall in blood pressure by a ganglionic blocker

Question 6

Maximum duration of action is seen with which of the following drugs?

Accepted Answer

Pancuronium

Answer

Atracurium

Answer

Rocuronium

Answer

Rapcuronium

Question 7

Which antiglaucoma drugs are safe to use in a patient with asthma?

Accepted Answer

Betaxolol

Answer

Timolol

Answer

Propranolol

Answer

All the above

Question 8

Which drugs would antagonize the interaction of catecholamines with adrenergic receptors?

Accepted Answer

Yohimbine

Answer

Methyldopa

Answer

Clonidine

Answer

Phenylephrine

Question 9

Cinnarizine, used for motion sickness, is a:

Accepted Answer

H1 antagonist

Answer

5HT4 antagonist

Answer

Antihistamine

Answer

NK1 antagonist

Question 10

Neostigmine used in the treatment of myasthenia gravis acts by:

Accepted Answer

Decreasing breakdown of acetylcholine

Answer

Increasing the number of receptors for acetylcholine

Answer

Increasing synthesis of acetylcholine

Answer

Increasing acetylcholine degradation

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?